Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/23014
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keefe, D. | - |
dc.contributor.author | Lees, J. | - |
dc.contributor.author | Horvath, N. | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Supportive Care in Cancer, 2006; 14(6):580-582 | - |
dc.identifier.issn | 0941-4355 | - |
dc.identifier.issn | 1433-7339 | - |
dc.identifier.uri | http://hdl.handle.net/2440/23014 | - |
dc.description | The original publication can be found at www.springerlink.com | - |
dc.description.abstract | Goals of work the aim of this paper was to review the initial use of Palifermin(rHu-KGF1) in a single institution, for the prevention of oral mucositis in high-dose chemotherapy and stem cell transplantation. Methods the case records of the first five patients treated with Palifermin at the Royal Adelaide Hospital Cancer Centre were reviewed, and incidence,severity and duration of the oral mucositis were recorded, as well as demographics and toxicities. Results two of the five patients developed grade 4 mucositis, and the remaining three patients developed grade 2 mucositis. Palifemin was well tolerated with only one patient developing a rash. Conclusions the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy. Palifermin was well tolerated. Obviously this single institution report is from a very small cohort of patients, but it is encouraging for the ease of use of this drug in the future. | - |
dc.description.statementofresponsibility | Dorothy Keefe, Jude Lees and Noemi Horvath | - |
dc.language.iso | en | - |
dc.publisher | Springer-Verlag | - |
dc.source.uri | http://www.springerlink.com/content/y304033x06457626/ | - |
dc.subject | Humans | - |
dc.subject | Stomatitis | - |
dc.subject | Drug Eruptions | - |
dc.subject | Busulfan | - |
dc.subject | Podophyllotoxin | - |
dc.subject | Melphalan | - |
dc.subject | Cyclophosphamide | - |
dc.subject | Carmustine | - |
dc.subject | Cytarabine | - |
dc.subject | Antineoplastic Agents | - |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject | Treatment Outcome | - |
dc.subject | Transplantation Conditioning | - |
dc.subject | Combined Modality Therapy | - |
dc.subject | Hematopoietic Stem Cell Transplantation | - |
dc.subject | Drug Administration Schedule | - |
dc.subject | Severity of Illness Index | - |
dc.subject | Incidence | - |
dc.subject | Primary Prevention | - |
dc.subject | Time Factors | - |
dc.subject | Adult | - |
dc.subject | Middle Aged | - |
dc.subject | Cancer Care Facilities | - |
dc.subject | South Australia | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.subject | Fibroblast Growth Factor 7 | - |
dc.title | Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00520-006-0048-3 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Keefe, D. [0000-0001-9377-431X] | - |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.